# The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer

> **NCT05822726** · NA · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 240 (estimated)

## Conditions studied

- Prostate Cancer
- PSMA
- p2PSA

## Interventions

- **DIAGNOSTIC_TEST:** Prostate biopsy

## Key facts

- **NCT ID:** NCT05822726
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05822726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05822726, "The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05822726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*